Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2009 (2009), Article ID 693014, 3 pages
http://dx.doi.org/10.1155/2009/693014
Case Report

Profound Muscle Weakness and Pain after One Dose of Actonel

Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA

Received 15 July 2009; Accepted 18 September 2009

Academic Editor: Mamede de Carvalho

Copyright © 2009 Irina Badayan and Merit E. Cudkowicz. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. M. Iqbal, “Osteoporosis: epidemiology, diagnosis, and treatment,” Southern Medical Journal, vol. 93, no. 1, pp. 2–18, 2000. View at Google Scholar
  2. Physicians' Desk Reference: PDR-Actonel Tablets, MICROMEDEX Healthcare, 2007.
  3. Muscular weakness assessment: use of normal isometric strength data, “The National Isometric Muscle Strength (NIMS) database consortium,” Archives of Physical Medicine and Rehabilitation, vol. 77, no. 12, pp. 1251–1255, 1996. View at Google Scholar
  4. U.S. Department of Health & Human Services, Bone Health and Osteoporosis: A Report of the Surgeon General, 2004.
  5. D. K. Wysowski and J. T. Chang, “Alendronate and risedronate: reports of severe bone, joint, and muscle pain,” Archives of Internal Medicine, vol. 165, no. 3, pp. 346–347, 2005. View at Google Scholar
  6. FDA Patient Safety News: Show # 54, Sever Bone and Muscle Pain with Bisphosphonates, August 2006.
  7. R. E. Hewitt, A. Lissina, A. E. Green, E. S. Slay, D. A. Price, and A. K. Sewell, “The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins,” Clinical and Experimental Immunology, vol. 139, no. 1, pp. 101–111, 2005. View at Publisher · View at Google Scholar · View at PubMed
  8. A. Diaz-Borjon, T. M. Seyler, N. L. Chen, and S. S. Lim, “Bisphosphonate-associated arthritis,” Journal of Clinical Rheumatology, vol. 12, no. 3, pp. 131–133, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. Drug Topics, 200 Brand Name Drugs by Units, 2007.
  10. L. Hazell and S. A. W. Shakir, “Under-reporting of adverse drug reactions: a systematic review,” Drug Safety, vol. 29, no. 5, pp. 385–396, 2006. View at Publisher · View at Google Scholar
  11. H. J. DeMonaco, “Patient- and physician-oriented web sites and drug surveillance: bisphosphonates and severe bone, joint, and muscle pain,” Archives of Internal Medicine, vol. 169, no. 12, pp. 1164–1166, 2009. View at Publisher · View at Google Scholar · View at PubMed